Recent research suggests a connection between weight loss drugs and hair loss. Specifically, individuals taking GLP-1 agonist medications like Mounjaro, Ozempic, and Wegovy have reported hair loss, and this new study involving around 50,000 participants appears to support that link.
GLP-1s are primarily employed to treat diabetes and obesity by mimicking hormones that help regulate blood sugar levels and suppress appetite.
Experts analyzed hair loss rates in adults using GLP-1s for managing diabetes compared to those taking other diabetes medications. Researchers from the University of Pennsylvania Health System noted that U.S. regulators have been made aware of the correlation between these drugs and hair loss, especially concerning semaglutide (found in Wegovy and Ozempic) and tirzepatide (Mounjaro).
This year alone, the UK Medicines and Healthcare products Regulatory Agency (MHRA) received 399 hair loss reports linked to tirzepatide and 148 related to semaglutide.
The recent study compared 12,004 patients using GLP-1s with 15,221 taking SGLT-2 inhibitors, and another group of 11,964 GLP-1 users with 11,233 on DPP-4 inhibitors. After adjusting for factors like age and weight, the findings revealed that GLP-1 users face a 37% higher risk of alopecia compared to those on SGLT-2 inhibitors, and a 68% higher risk compared to DPP-4 users.
This link appears to be associated mainly with non-scarring alopecia, which means hair follicles remain intact, allowing for possible regrowth.
In the British Medical Journal, the researchers reported, “Case reports and analyses from the US FDA’s Adverse Event Reporting System have detailed instances of hair loss following the start of a GLP-1 receptor agonist, particularly semaglutide and tirzepatide. The FDA is currently assessing this potential safety signal.”
They noted that while hair loss isn’t usually dangerous, it can significantly affect a person’s self-esteem and quality of life, which might lead to issues with treatment adherence.
As for why hair loss may occur with these medications, the most plausible reason appears to be related to weight loss and reduced calorie intake. They speculated that restricting calories might induce physiological stress and lead to nutrient deficiencies, such as iron and biotin, disrupting the hair growth cycle.
There could also be metabolic, hormonal, and immunological effects from GLP-1 receptor agonists impacting hair follicle dynamics. For instance, changes in thyroid function and delayed gastric emptying have been noted, which could affect the absorption of medications like thyroid hormones and sex hormone therapies.
The researchers concluded that their findings add more systematic evidence to support previous anecdotal safety concerns about these medications.
Additionally, it was reported that these drugs might also be linked to a decrease in the number of alcohol-dependent people being hospitalized, as some studies suggest they could help reduce alcohol consumption. However, U.S. researchers have cautioned that the evidence in this area remains limited and somewhat inconsistent.
